Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial

Lancet

Volumn 355, Issue 9218, 2000, Pages 1845-1850

  Nicholson, K G ^a   Aoki, F Y ^b   Osterhaus, A D M E ^c   Trottier, S ^d   Carewicz, O ^g   Mercier, C H ^g   Rode, A ^e   Kinnersley, N ^f   Ward, P ^f  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d LAVAL UNIVERSITY   (Canada)

^e Humana Sandvika AS   (Norway)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SYMPTOM; TREATMENT OUTCOME; VIRUS SHEDDING; VOMITING;

EID: 0034720503     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02288-1     Document Type: Article

References (24)

1. Schoenbaum S.C. Economic impact of influenza. the individual's perspective Am J Med. 82:1987;26-30.
2. Sullivan K.M. Health impact of influenza in the United States. Pharmacoeconomics. 9:1996;26-33.
3. Keech M., Scott A.J., Ryan P.J.J. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med. 48:1998;85-90.
4. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 47:1999;1-26.
5. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate- and high-risk senior citizens. Arch Intern Med. 158:1998;1769-1776.
6. Nicholson K.G. Use of antivirals in influenza in the elderly. prophylaxis and therapy Gerontology. 42:1996;280-289.
7. Colman P.M., Varghese J.N., Laver W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 303:1983;41-44.
8. Colman P.M. Neuraminidase: enzyme and antigen. Krug R.M. The influenza viruses. 1989;175-218 Plenum Press, New York.
9. von Itzstein M., Wu W.Y., Kok G.B.et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
10. Kim C.U., Lew W., Williams M.A.et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site. design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J Am Chem Soc. 119:1997;681-690.
11. Woods J.M., Bethell R.C., Coates J.A.V.et al. 4-guanidino-2,4-dideoxy-2,3 dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 37:1993;1473-1479.
12. Mendel D.B., Tai C.Y., Escarpe P.A.et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 42:1998;640-646.
13. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 352:1998;1877-1881.
14. Li W., Escarpe P.A., Eisenberg E.J.et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 42:1998;647-653.
15. Sidwell R.W., Huffman J.H., Barnard D.L.et al. Inhibition of influenza virus infections in mice by GS 4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 37:1998;107-120.
16. Hayden F.G., Treanor J.T., Fritz R.S.et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. randomized, controlled trials for prevention and treatment JAMA. 282:1999;1240-1246.
17. Dowdle W.N., Kendal A.P., Noble G.R. Influenza viruses. Lennette E.H., Schmidt N.J. Diagnostic procedures for viral, rickettsial, and chlamydial infections, 5th edn. 1979;603-605 American Public Health Association, Washington, DC.
18. Hayden F.G., Osterhaus A.D.M.E., Treanor J.J.et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 337:1997;874-880.
19. Smith A.P., Thomas M., Brockman P., Kent J., Nicholson K.G. Effect of influenza virus B infection on human performance. BMJ. 306:1993;760-761.
20. Ogilvie M.M. Antiviral prophylaxis and treatment in chickenpox. a review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection J Infect. 36:1998;31-38.
21. Wood M.J., Shukla S., Fiddian A.P., Crooks R.J. Treatment of acute herpes zoster. effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain J Infect Dis. 178:1998;81-84.
22. Nicholson K.G. Human influenza. Nicholson K.G., Webster R.G., Hay A.J. Textbook of influenza. 1998;219-264 Blackwell Science, Oxford.
23. Glezen W.P., Decker M., Joseph S.W., Mercready R.G. Jr. Acute respiratory disease associated with influenza epidemics in Houston, 1981-83. J Infect Dis. 155:1987;1119-1126.
24. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 37:1999;471-484.